{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:27:48Z","timestamp":1793528868616,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:06:43Z","timestamp":1772863603000},"page":"1080-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4602-979X","authenticated-orcid":false,"given":"Renee A.G.","family":"Lijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanneke B.","family":"Ringia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Claps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry N.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.A.T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-6427","authenticated-orcid":false,"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.02.009_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.02.009_b0010","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.urology.2014.06.032","article-title":"Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens","volume":"84","author":"Cai","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.euo.2026.02.009_b0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2014part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.009_b0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.02.009_b0025","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.3390\/jcm13154349","article-title":"The prognostic significance of histological subtypes in patients with muscle-invasive bladder cancer: an overview of the current literature","volume":"13","author":"Claps","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2026.02.009_b0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.02.009_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urolonc.2007.07.010","article-title":"The impact of variant histology on the outcome of bladder cancer treated with curative intent","volume":"27","author":"Black","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.009_b0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskim\u00e4e","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.009_b0045","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.009_b0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","article-title":"Staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer","volume":"5","author":"Voskuilen","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.009_b0055","series-title":"TNM classification of malignant tumours","author":"James","year":"2017"},{"key":"10.1016\/j.euo.2026.02.009_b0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0972-3919.112718","article-title":"Detecting primary bladder cancer using delayed (18)F-2-fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography imaging after forced diuresis","volume":"27","author":"Mertens","year":"2012","journal-title":"Indian J Nucl Med"},{"key":"10.1016\/j.euo.2026.02.009_b0065","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/RLU.0000000000001780","article-title":"Enhanced application of 18F-FDG PET\/CT in bladder cancer by adding early dynamic acquisition to a standard delayed PET protocol","volume":"42","author":"Yoon","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.euo.2026.02.009_b0070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12149-018-1280-x","article-title":"Detectability of residual invasive bladder cancer in delayed 18F-FDG PET imaging with oral hydration using 500 mL of water and voiding-refilling","volume":"32","author":"Higashiyama","year":"2018","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.euo.2026.02.009_b0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12149-012-0614-3","article-title":"Is whole-body fluorine-18 fluorodeoxyglucose PET\/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?","volume":"26","author":"Yang","year":"2012","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.euo.2026.02.009_b0080","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/MOU.0000000000000798","article-title":"18F-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography in muscle-invasive bladder cancer","volume":"30","author":"Einerhand","year":"2020","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2026.02.009_b0085","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/jcm12103367","article-title":"The implementation of FDG PET\/CT for staging bladder cancer: changes in the detection and characteristics of occult nodal metastases at upfront radical cystectomy?","volume":"12","author":"Einerhand","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2026.02.009_b0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000488200","article-title":"Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis","volume":"95","author":"Ha","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.euo.2026.02.009_b0095","doi-asserted-by":"crossref","first-page":"833.e9","DOI":"10.1016\/j.urolonc.2021.04.027","article-title":"The role of 18F-FDG PET\/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer","volume":"39","author":"Moussa","year":"2021","journal-title":"Urol Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.euo.2026.02.009_b0100","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.euo.2026.02.009_b0105","doi-asserted-by":"crossref","first-page":"vii27","DOI":"10.1093\/annonc\/mds268","article-title":"Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Colombo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.02.009_b0110","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.02.009_b0115","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2214\/ajr.174.4.1741005","article-title":"FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features","volume":"174","author":"Berger","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.euo.2026.02.009_b0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clgc.2021.03.002","article-title":"The diagnostic value of FDG-PET\/CT for urachal cancer","volume":"19","author":"Stokkel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.02.009_b0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2026.02.009_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.euo.2026.02.009_b0135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2214\/AJR.19.22467","article-title":"FDG PET\/CT and CT findings of renal cell carcinoma with sarcomatoid differentiation","volume":"215","author":"Zhu","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.euo.2026.02.009_b0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13550-025-01206-w","article-title":"Diagnostic and prognostic role of 18F-FDG PET\/CT for sarcomatoid differentiation in renal cell carcinoma","volume":"15","author":"Na","year":"2025","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.euo.2026.02.009_b0145","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.euo.2025.03.019","article-title":"Utility of fluorodeoxyglucose positron emission tomography\/computed tomography in detecting lymph node involvement in comparison to conventional imaging in patients with bladder cancer with variant histology","volume":"8","author":"Bizzarri","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.009_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2022.09.017","article-title":"Positron emission tomography\/computed tomography for staging of bladder cancer: a continuing clinical controversy","volume":"83","author":"Mertens","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.009_b0155","doi-asserted-by":"crossref","first-page":"S1200","DOI":"10.1016\/j.annonc.2023.09.1010","article-title":"2361MO Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE]","volume":"34","author":"Sridhar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.02.009_b0160","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1007\/s00259-023-06222-3","article-title":"Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies","volume":"50","author":"Dimitrakopoulou-Strauss","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.02.009_b0165","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2025.43.5_suppl.769","article-title":"Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): a phase 2 trial","volume":"43","author":"Raychaudhuri","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:32:19Z","timestamp":1793525539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2588931126000465"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}